Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing ...

Merck (NYSE:MRK) on Thursday announced plans to invest $895M to expand a manufacturing facility in Kansas, becoming the ...

A new manufacturing plant in De Soto will be a Center of Excellence for the global company, along with expanded R&D ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Merck maintained its 2025 full-year revenue ... supported by a robust pipeline and significant investments in manufacturing and R&D. Management emphasized a focus on navigating short-term ...

Rahway, New Jersey Friday, May 9, 2025, 09:00 Hrs [IST] ...

Merck & Co's CEO has portrayed innovative ... Frazier defended big pharma's R&D investment, and took a swipe at opportunist firms that have inflated prices of older medicines.

Merck (NYSE:MRK) is set to showcase significant research advancements, including updates on its KEYTRUDA indications at the upcoming ASCO Annual Meeting, which could enhance its oncology footprint.

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

The investment comprising $860M allotted for the site's existing production facility and $35M allocated for R&D labs is set to boost the production capacity of Merck Animal Health’s large ...

The $895 million capital expansion will be constructed on an existing Merck-owned property that is the site of its biologics facility in De Soto, Kansas. It includes an $860 million investment in ...